Literature DB >> 16399446

Outcomes after surgical treatment of colorectal cancer liver metastases.

Steven A Curley1.   

Abstract

Many patients with metastatic colorectal cancer present with liver-only disease that is amenable to surgical resection. While patients with more than three or four hepatic metastases have traditionally been considered poor candidates for surgical treatment, a review of extant data shows that a sizable proportion of these patients can have long-term survival with surgical intervention. Our group performed a prospective study in 418 patients with proven liver-only disease to determine outcomes with resection alone and with resection plus radiofrequency ablation (RFA) or RFA alone in patients with unresectable disease. Overall 5-year survival was significantly greater in patients receiving resection alone, but 4-year survival rates were substantial in patients receiving resection plus RFA or RFA alone (P <.0001); survival with the latter two approaches was significantly better than that with chemotherapy alone (P = .0017). Although the presence of more than three metastases was associated with a significantly increased risk of death compared with a solitary metastasis on multivariate analysis, patients with more than three metastases had a 5-year survival rate in excess of 50%. Surgical resection and ablation should be considered as part of a multimodality therapeutic approach to both primary and secondary hepatic malignancies.

Entities:  

Mesh:

Year:  2005        PMID: 16399446     DOI: 10.1053/j.seminoncol.2005.06.011

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  13 in total

1.  Long-term results of radiofrequency ablation for unresectable colorectal liver metastases: a potentially curative intervention.

Authors:  A A J M Van Tilborg; M R Meijerink; C Sietses; J H T M Van Waesberghe; M O Mackintosh; S Meijer; C Van Kuijk; P Van Den Tol
Journal:  Br J Radiol       Date:  2010-12-15       Impact factor: 3.039

Review 2.  Regional hepatic therapies: an important component in the management of colorectal cancer liver metastases.

Authors:  Abdul Saied; Steven C Katz; N Joseph Espat
Journal:  Hepatobiliary Surg Nutr       Date:  2013-04       Impact factor: 7.293

3.  Breast cancer liver metastases: US-guided percutaneous radiofrequency ablation--intermediate and long-term survival rates.

Authors:  Maria Franca Meloni; Anita Andreano; Paul F Laeseke; Tito Livraghi; Sandro Sironi; Fred T Lee
Journal:  Radiology       Date:  2009-08-25       Impact factor: 11.105

4.  Laparoscopic hepatectomy versus open hepatectomy for colorectal cancer liver metastases: comparative study with propensity score matching.

Authors:  Xavier Untereiner; Audrey Cagniet; Riccardo Memeo; Stylianos Tzedakis; Tullio Piardi; François Severac; Didier Mutter; Reza Kianmanesh; Jacques Marescaux; Daniele Sommacale; Patrick Pessaux
Journal:  Hepatobiliary Surg Nutr       Date:  2016-08       Impact factor: 7.293

Review 5.  Survival and symptomatic benefit from palliative primary tumor resection in patients with metastatic colorectal cancer: a review.

Authors:  Andrew Eisenberger; R Lawrence Whelan; Alfred I Neugut
Journal:  Int J Colorectal Dis       Date:  2008-03-11       Impact factor: 2.571

6.  In defense of body CT.

Authors:  Cynthia H McCollough; Luís Guimarães; Joel G Fletcher
Journal:  AJR Am J Roentgenol       Date:  2009-07       Impact factor: 3.959

7.  Proteomic Analysis of Primary Colon Cancer and Synchronous Solitary Liver Metastasis.

Authors:  Eun-Kyung Kim; Min-Jeong Song; Yunjae Jung; Won-Suk Lee; Ho Hee Jang
Journal:  Cancer Genomics Proteomics       Date:  2019 Nov-Dec       Impact factor: 4.069

8.  Impact of peri-operative bevacizumab on survival in patients with resected colorectal liver metastases: an analysis of the LiverMetSurvey.

Authors:  Zhixia Rong; Guillaume Martel; Franck Vandenbroucke-Menu; René Adam; Réal Lapointe
Journal:  HPB (Oxford)       Date:  2014-04       Impact factor: 3.647

9.  Open versus laparoscopic liver resection for colorectal liver metastases (the Oslo-CoMet Study): study protocol for a randomized controlled trial.

Authors:  Åsmund Avdem Fretland; Airazat M Kazaryan; Bjørn Atle Bjørnbeth; Kjersti Flatmark; Marit Helen Andersen; Tor Inge Tønnessen; Gudrun Maria Waaler Bjørnelv; Morten Wang Fagerland; Ronny Kristiansen; Karl Øyri; Bjørn Edwin
Journal:  Trials       Date:  2015-03-04       Impact factor: 2.279

10.  Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial.

Authors:  Zeinab Hamidou; Benoist Chibaudel; Mohamed Hebbar; Marine Hug de Larauze; Thierry André; Christophe Louvet; David Brusquant; Marie-Line Garcia-Larnicol; Aimery de Gramont; Franck Bonnetain
Journal:  PLoS One       Date:  2016-06-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.